8-K current report · filed Nov 18, 2026

Wave Life Sciences Ltd. (WVE) 8-K Current Report: November 18, 2026

Item 5.02Item 5.07WVE overview

Short answer

Wave Life Sciences Ltd. (WVE) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved 11,000,000 additional shares for the 2021 Equity Incentive Plan.

Wave Life Sciences Ltd. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Stockholders approved 11,000,000 additional shares for the 2021 Equity Incentive Plan
  • Expanded equity pool supports employee retention and hiring, but increases potential shareholder dilution
  • Amendment approved November 12, 2026, with plan details in Exhibit 10.1

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • 84% quorum: 166.2M of 197.2M eligible shares represented at the November 12 annual meeting
  • Nine incumbent directors re-elected through the 2027 annual meeting, with Ken Takanashi receiving the highest withheld vote count at 22.7M
  • KPMG ratified as independent auditor for 2026, with 165.8M votes for and 338,795 against
  • 2021 Equity Incentive Plan amendment approved, with 119.8M votes for versus 22.9M against
  • Executive compensation approved on an advisory basis, with 133.8M votes for versus 8.9M against

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Wave Life Sciences Ltd. 8-K filings

Get the next WVE 8-K as it lands

Follow WVE for push alerts, or ask the research agent what this filing means.